Hey FDA, We Need the Orphan Products Board NOW!

In 1983, Congress passed the Orphan Drug Act. The goal was to facilitate the development of drugs and devices to treat rare diseases. Within the legislation was a provision to establish an Orphan Products Board (OPB). The board’s purpose was to orchestrate action between government regulatory bodies, pharmaceutical companies and advocacy groups.

Continue reading